GSK Avandia/Insulin Use Based On 220-Patient Study Showing No Cardio Risk

03 Mar 2003

• By The Pink Sheet

GlaxoSmithKline's long-awaited approval of Avandia in combination with insulin is based on a 220-patient study showing no cardiovascular safety signal in type 2 diabetes patients

GSK Avandia/Insulin Use Based On 220-Patient Study Showing No Cardio Risk

More from Archive

More from Pink Sheet